KRIBIOLISA™ Monalizumab ELISA

SKU: KBI1476 Category:

₹58,000.00

Enzyme Immunoassay for the estimation of Monalizumab in serum and plasma.

About the kit:
– Uses anti-idiotypic monoclonal antibodies which ensures higher specificity, and low cross reactivity.
– Recovery rates are between 85 – 115%
– Validated as per US FDA guidelines for Bioassays
– Precision CV<10%

Availability: 3 – 4 Weeks | Pack Size: 1 x 96 wells

Add to wishlist

Description

Background:
Monalizumab is a monoclonal antibody designed to target the NKG2A receptor, an inhibitory receptor expressed on natural killer (NK) cells and certain T cells. By blocking NKG2A, monalizumab aims to enhance the anti-tumor immune response. The antibody has shown promise in cancer immunotherapy, particularly in combination with other immune checkpoint inhibitors. The application of monalizumab lies in its potential to boost the activity of immune cells against cancer cells. Clinical trials are underway to evaluate its efficacy in various solid tumors and hematological malignancies. This immunotherapeutic approach seeks to overcome the immunosuppressive mechanisms employed by tumors, contributing to a more effective immune response against cancer.

Additional information

Sample Type

Serum (100 ul), EDTA Plasma (100 ul), Heparin Plasma (100 ul), Citrate Plasma (100 ul)
Calibration Range

0 ng/ml – 2000 ng/ml
Specificity

80% – 120% to Monalizumab
Cross Reactivity

< 0.5% cross-reactivity observed with related biomarker.
Interference

No significant interference observed with available related molecules.
Regulatory Status

Research Use Only
Research Area

Biosimilars / Therapeutic Drug Monitoring
Entez Gene ID

IPH2201 Human
Alternate Names / Synonyms

Monalizumab
Validation

The kit uses a biosimilar research grade standard / calibrator. The standard / calibrator has been validated against WHO/NIBSC standard and/or against commercially sourced innovator drug where available. Please refer the IFU for more details.
Disclaimer

Trade name indicated is for reference purposes only. It does not reflect any licences or patent usage. The tradename is the registered trademark of the respective owners only.
Long Name

Protein Based Therapies – Monoclonal Antibody

Related products